WOCKHARDT Financial Statement Analysis
|
||
|
The Revenues of WOCKHARDT have increased by 7.65% YoY .
The Earnings Per Share (EPS) of WOCKHARDT has increased by Positive YoY. |
||
WOCKHARDT Last 5 Annual Financial Results
[BOM: 532300|NSE : WOCKPHARMA]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹3,012 Cr | ₹2,798 Cr | ₹2,651 Cr | ₹3,230 Cr | ₹2,708 Cr |
| Expenses | ₹2,619 Cr | ₹2,759 Cr | ₹2,550 Cr | ₹2,932 Cr | ₹2,771 Cr |
| Operating Profit (Excl OI) | ₹393 Cr | ₹39 Cr | ₹101 Cr | ₹298 Cr | ₹-63 Cr |
| Other Income | ₹62 Cr | ₹83 Cr | ₹122 Cr | ₹20 Cr | ₹132 Cr |
| Interest | ₹254 Cr | ₹305 Cr | ₹302 Cr | ₹299 Cr | ₹249 Cr |
| Depreciation | ₹217 Cr | ₹223 Cr | ₹251 Cr | ₹247 Cr | ₹246 Cr |
| Profit Before Tax | ₹-16 Cr | ₹-420 Cr | ₹-624 Cr | ₹-411 Cr | ₹-568 Cr |
| Profit After Tax | ₹-57 Cr | ₹-472 Cr | ₹-621 Cr | ₹-279 Cr | ₹-297 Cr |
| Consolidated Net Profit | ₹-47 Cr | ₹-463 Cr | ₹-559 Cr | ₹-244 Cr | ₹686 Cr |
| Earnings Per Share (Rs) | ₹13.15 | ₹-2.90 | ₹-30.06 | ₹-38.82 | ₹-16.94 |
| PAT Margin (%) | 5.13 | -1.47 | -13.09 | -14.53 | -5.44 |
| ROE(%) | 4.29 | -1.48 | -14.12 | -17.32 | -7.77 |
| ROCE(%) | 6.79 | 4.07 | -2.15 | -5.88 | -1.96 |
| Total Debt/Equity(x) | 0.43 | 0.43 | 0.63 | 0.57 | 0.49 |
Key Financials |
||
| Market Cap | : | ₹ 30,644.3 Cr |
| Revenue (TTM) | : | ₹ 3,564.0 Cr |
| Net Profit(TTM) | : | ₹ 414.0 Cr |
| EPS (TTM) | : | ₹ 25.5 |
| P/E (TTM) | : | 74.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| WOCKHARDT | -0.4% | 2% | 20.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 1% | -2.7% | 15.7% |
| DIVIS LABORATORIES | 0.7% | 17.1% | 40.1% |
| TORRENT PHARMACEUTICALS | -0.3% | -3.7% | 37.9% |
| CIPLA | -0.3% | 2.3% | -8.1% |
| DR REDDYS LABORATORIES | -1.4% | 0.7% | -6.2% |
| MANKIND PHARMA | -1.2% | -7.2% | -3.5% |
| LUPIN | -2.9% | -8.5% | 12.4% |
| ZYDUS LIFESCIENCES | -1.1% | 0.6% | 12.1% |
WOCKHARDT Revenues
[BOM: 532300|NSE : WOCKPHARMA]
| Y-o-Y | 7.65 % |
| 5 Yr CAGR | 2.70 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹3,012 Cr | 7.65 | |
| Mar2025 | ₹2,798 Cr | 5.55 | |
| Mar2024 | ₹2,651 Cr | -17.93 | |
| Mar2023 | ₹3,230 Cr | 19.28 | |
| Mar2022 | ₹2,708 Cr | - | |
WOCKHARDT Operating Profit
[BOM: 532300|NSE : WOCKPHARMA]
| Y-o-Y | 907.69 % |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹393 Cr | 907.69 | |
| Mar2025 | ₹39 Cr | -61.39 | |
| Mar2024 | ₹101 Cr | -66.11 | |
| Mar2023 | ₹298 Cr | Positive | |
| Mar2022 | ₹-63 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 838.85 % |
| 5 Yr CAGR | Positive |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 13.05% | 838.85 | |
| Mar2025 | 1.39% | -63.52 | |
| Mar2024 | 3.81% | -58.72 | |
| Mar2023 | 9.23% | Positive | |
| Mar2022 | -2.33% | - | |
WOCKHARDT Profit After Tax
[BOM: 532300|NSE : WOCKPHARMA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹-47 Cr | Negative | |
| Mar2025 | ₹-463 Cr | Negative | |
| Mar2024 | ₹-559 Cr | Negative | |
| Mar2023 | ₹-244 Cr | Negative | |
| Mar2022 | ₹686 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 5.13 % | Positive | |
| Mar2025 | -1.47 % | Negative | |
| Mar2024 | -13.09 % | Negative | |
| Mar2023 | -14.53 % | Negative | |
| Mar2022 | -5.44 % | - | |
WOCKHARDT Earnings Per Share (EPS)
[BOM: 532300|NSE : WOCKPHARMA]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹13 | Positive | |
| Mar2025 | ₹-2.90 | Negative | |
| Mar2024 | ₹-30 | Negative | |
| Mar2023 | ₹-39 | Negative | |
| Mar2022 | ₹-17 | - | |
WOCKHARDT Return on Capital Employed (ROCE)
[BOM: 532300|NSE : WOCKPHARMA]
| Y-o-Y | 66.83 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 6.79% | 66.83 | |
| Mar2025 | 4.07% | Positive | |
| Mar2024 | -2.15% | Negative | |
| Mar2023 | -5.88% | Negative | |
| Mar2022 | -1.96% | - | |
WOCKHARDT Share Price vs Sensex
| Current Share Price | : | ₹1,885.8 |
| Current MarketCap | : | ₹ 30,644.3 Cr |
| Updated EOD on | : | Aug 21,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WOCKHARDT | -0.4% |
2% |
20.1% |
| SENSEX | -0.6% |
1% |
-3.7% |
WOCKHARDT related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE SMALLCAP SELECT INDEX | 1.5% | 6.4% | 16.8% |
| BSE 250 SMALLCAP INDEX | 0.4% | 3.1% | 8.1% |
| BSE 400 MIDSMALLCAP INDEX | 0.2% | 2.6% | 9.7% |
| BSE 1000 | -0.3% | 1.9% | 4% |
| BSE 500 | -0.4% | 1.7% | 3.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 100 | 1.2% | 4.4% | 13.4% |
| NIFTY SMALLCAP 50 | 1.2% | 5.3% | 17.1% |
| NIFTY SMALLCAP 250 | 0.7% | 3.1% | 10.1% |
| NIFTY SMALLCAP 500 | 0.7% | 3.7% | NA |
| NIFTY MIDSMALLCAP400 50:50 | 0.3% | 2.6% | NA |
You may also like the below Video Courses
FAQ about WOCKHARDT Financials
How the annual revenues of WOCKHARDT have changed ?
The Revenues of WOCKHARDT have increased by 7.65% YoY .
How the Earnings per Share (EPS) of WOCKHARDT have changed?
The Earnings Per Share (EPS) of WOCKHARDT has increased by Positive YoY .
Check out Intrinsic Value of Peers of WOCKHARDT
Compare Stock Analytics of Peers of WOCKHARDT
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
